Mieke Zwager

Dr. Mieke Zwager

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in IEEE Transactions on Medical Imaging
Verified
Journal Article
Closed access
RVRuchika Verma
Ruchika Verma
NKNeeraj Kumar
Neeraj Kumar
APAbhijeet Patil
Abhijeet Patil
NKNikhil Cherian Kurian
Nikhil Cherian Kurian
SRSwapnil Rane
Swapnil Rane
ASAmit Sethi
Amit Sethi
Detecting various types of cells in and around the tumor matrix holds a special significance in characterizing the tumor micro-environment for cancer prognostication and research. Automating the tasks of detecting, segmenting, and classifying nuclei can free up the pathologists’ time for higher value tasks and reduce errors due to fatigue and subjectivity. To encourage the computer vision research community to develop and test algorithms for these tasks, we prepared a large and diverse dataset of nucleus boundary annotations and class labels. The dataset has over 46,000 nuclei from 37 hospitals, 71 patients, four organs, and four nucleus types. We also organized a challenge around this dataset as a satellite event at the International Symposium on Biomedical Imaging (ISBI) in April 2020. The challenge saw a wide participation from across the world, and the top methods were able to match inter-human concordance for the challenge metric. In this paper, we summarize the dataset and the key findings of the challenge, including the commonalities and differences between the methods developed by various participants. We have released the MoNuSAC2020 dataset to the public.

9 January 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
MZMieke Zwager
Mieke Zwager
RBRico Bense
Rico Bense
SWStijn Waaijer
Stijn Waaijer
SQSi-Qi Qiu
Si-Qi Qiu
HTHetty Timmer-Bosscha
Hetty Timmer-Bosscha
BVBert van der Vegt
Bert van der Vegt
Purpose: The number of M1-like and M2-like tumour-associated macrophages (TAMs) and their ratio can play a role in breast cancer development and progression. Early clinical trials using macrophage targeting compounds are currently ongoing. However, the most optimal detection method of M1-like and M2-like macrophage subsets and their clinical relevance in breast cancer is still unclear. We aimed to optimize the assessment of TAM subsets in different breast cancer subtypes, and therefore related TAM subset numbers and ratio to clinicopathological characteristics and clinical outcome. Methods: Tissue microarrays of 347 consecutive primary Luminal-A, Luminal-B, HER2-positive and triple-negative tumours of patients with early-stage breast cancer were serially sectioned and immunohistochemically stained for the pan-macrophage marker CD68 and the M2-like macrophage markers CD163, CSF-1R and CD206. TAM numbers were quantified using a digital image analysis algorithm. M1-like macrophage numbers were calculated by subtracting M2-like TAM numbers from the total TAM number. Results: M2-like markers CD163 and CSF-1R showed a moderate positive association with each other and with CD68 (r ≥ 0.47), but only weakly with CD206 (r ≤ 0.06). CD68 + , CD163 + and CSF-1R + macrophages correlated with tumour grade in Luminal-B tumours (P < 0.001). Total or subset TAM numbers did not correlate with disease outcome in any breast cancer subtype. Conclusion: In conclusion, macrophages and their subsets can be detected by means of a panel of TAM markers and are related to unfavourable clinicopathological characteristics in Luminal-B breast cancer. However, their impact on outcome remains unclear. Preferably, this should be determined in prospective series.

14 February 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
JBJorianne Boers
Jorianne Boers
BEBertha van Essen Eisses
Bertha van Essen Eisses
MZMieke Zwager
Mieke Zwager
JGJasper van Geel
Jasper van Geel
FBFrederike Bensch
Frederike Bensch
CSCarolina P Schröder
Carolina P Schröder
Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18F]FDG uptake was expressed as maximum standardized uptake value (SUVmax) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [18F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18F]FDG uptake, [18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332).

5 August 2024 in Histopathology
Verified
Journal Article
Open access
MZMieke Zwager
Mieke Zwager
SYShibo YU
Shibo YU
HBHenk J Buikema
Henk J Buikema
GBGeertruida de Bock
Geertruida de Bock
TRThomas W Ramsing
Thomas W Ramsing
BVBert van der Vegt
Bert van der Vegt
Aim: Manual detection and scoring of Ki67 hotspots is difficult and prone to variability, limiting its clinical utility. Automated hotspot detection and scoring by digital image analysis (DIA) could improve the assessment of the Ki67 hotspot proliferation index (PI). This study compared the clinical performance of Ki67 hotspot detection and scoring DIA algorithms based on virtual dual staining (VDS) and deep learning (DL) with manual Ki67 hotspot PI assessment.Methods: Tissue sections of 135 consecutive invasive breast carcinomas were immunohistochemically stained for Ki67. Two DIA algorithms, based on VDS and DL, automatically determined the Ki67 hotspot PI. For manual assessment; two independent observers detected hotspots and calculated scores using a validated scoring protocol.Results: Automated hotspot detection and assessment by VDS and DL could be performed in 73% and 100% of the cases, respectively. Automated hotspot detection by VDS and DL led to higher Ki67 hotspot PIs (mean 39.6% and 38.3%, respectively) compared to manual consensus Ki67 PIs (mean 28.8%). Comparing manual consensus Ki67 PIs with VDS Ki67 PIs revealed substantial correlation (r = 0.90), while manual consensus versus DL Ki67 PIs demonstrated high correlation (r = 0.95).Conclusion: Automated Ki67 hotspot detection and analysis correlated strongly with manual Ki67 assessment and provided higher PIs compared to manual assessment. The DL‐based algorithm outperformed the VDS‐based algorithm in clinical applicability, because it did not depend on virtual alignment of slides and correlated stronger with manual scores. Use of a DL‐based algorithm may allow clearer Ki67 PI cutoff values, thereby improving the clinical usability of Ki67.

6 December 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MZMieke Zwager
Mieke Zwager
IHIris Holt-Kedde
Iris Holt-Kedde
HTHetty Timmer-Bosscha
Hetty Timmer-Bosscha
GBGeertruida de Bock
Geertruida de Bock
PWPaul M. N. Werker
Paul M. N. Werker
MAMarlous Arjaans
Marlous Arjaans

20 November 2025 in Laboratory Investigation
Verified
Journal Article
Open access
MHMaaike Anna Hempenius
Maaike Anna Hempenius
MZMieke Zwager
Mieke Zwager
JTJeppe Thagaard
Jeppe Thagaard
LSLorian Slagter-Menkema
Lorian Slagter-Menkema
HBHenk J. Buikema
Henk J. Buikema
BVBert van der Vegt
Bert van der Vegt
Trastuzumab-deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), improves overall survival in patients with breast cancer showing low or ultralow HER2 expression. Differences in HER2 test results have been reported between various HER2 assays and between primary tumors and metastases, but an objective comparison with incorporation of the new HER2-ultralow cutoff values is needed. This study aimed to assess the performance of 4 routine clinical-grade HER2 assays across and between primary tumors and their metastases using digital image analysis. Primary tumors and metastases from 193 patients with breast cancer who participated in the IMaging PAtients for Cancer drug selecTion-Metastatic Breast Cancer trial were incorporated into 6 tissue microarrays. Samples were stained by 4 laboratories using their routine HER2 immunohistochemistry protocols: 4B5 ultraView, 4B5 OptiView, SP3, and HercepTest (DG44). HER2 scores were determined using digital image analysis. The 4 HER2 assays showed significant differences in HER2 status in both primary tumors and metastases. Eighty-five matched primary tumors and metastases were analyzed to investigate concordance in HER2 status. Although no significant differences were found in HER2 scores between primary tumors and metastases for SP3 and both 4B5 assays, DG44 showed significantly higher HER2 scores in the metastasis (P = .004). Concordance between primary tumors and metastases was highest for 4B5 ultraView (69.4%), followed by SP3 (61.2%) and 4B5 OptiView (51.8%). DG44 showed the most variability, with only 36.5% of matched samples receiving the same HER2 category. DG44 identified a significantly higher proportion of HER2-(ultra)low cases and showed the most variability in HER2 status between matched primary tumors and metastases compared with 4B5 and SP3. The choice of HER2 assay can lead to discrepancies in HER2 status assessment, which could directly influence patient eligibility for trastuzumab-deruxtecan treatment.